New shot could help teens with rare, severe high cholesterol
NCT ID NCT07473843
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called zodasiran in 12 teens aged 12 to 17 with homozygous familial hypercholesterolemia, a rare genetic condition causing very high cholesterol. The drug is given as a shot under the skin. The main goal is to see if it safely lowers bad cholesterol after 12 months. Participants must already be on other cholesterol-lowering treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New registry tracks Real-World safety of cholesterol drug lomitapide
- New repository aims to unlock secrets of rare, deadly cholesterol disease
- Worldwide effort to unlock secrets of rare cholesterol disease
- New drug shows promise for rare High-Cholesterol disease
- Experimental drug targets stubborn cholesterol in rare disease
- New shot aims to slash sky-high cholesterol in rare genetic disease